Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Clay Thorp sold 8,500 shares of the firm’s stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $7.49, for a total transaction of $63,665.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Clay Thorp also recently made the following trade(s):

  • On Thursday, September 14th, Clay Thorp sold 6,000 shares of Clearside Biomedical stock. The shares were sold at an average price of $7.52, for a total transaction of $45,120.00.
  • On Friday, September 15th, Clay Thorp sold 24,500 shares of Clearside Biomedical stock. The shares were sold at an average price of $7.52, for a total transaction of $184,240.00.
  • On Tuesday, August 8th, Clay Thorp sold 5,000 shares of Clearside Biomedical stock. The shares were sold at an average price of $7.98, for a total transaction of $39,900.00.
  • On Monday, August 7th, Clay Thorp sold 4,500 shares of Clearside Biomedical stock. The shares were sold at an average price of $8.02, for a total transaction of $36,090.00.
  • On Wednesday, August 9th, Clay Thorp sold 24,500 shares of Clearside Biomedical stock. The shares were sold at an average price of $7.57, for a total transaction of $185,465.00.

Clearside Biomedical, Inc. (NASDAQ CLSD) opened at 7.60 on Friday. The company has a 50-day moving average of $7.68 and a 200-day moving average of $7.97. Clearside Biomedical, Inc. has a 1-year low of $6.50 and a 1-year high of $25.08. The firm’s market capitalization is $192.55 million.

Clearside Biomedical (NASDAQ:CLSD) last posted its quarterly earnings results on Wednesday, August 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.13). Clearside Biomedical had a negative return on equity of 65.78% and a negative net margin of 27,225.52%. The firm had revenue of $0.13 million for the quarter. On average, equities analysts predict that Clearside Biomedical, Inc. will post ($2.10) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Clay Thorp Sells 8,500 Shares of Clearside Biomedical, Inc. (CLSD) Stock” was posted by Daily Political and is the property of of Daily Political. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2017/09/17/clay-thorp-sells-8500-shares-of-clearside-biomedical-inc-clsd-stock.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. ProShare Advisors LLC raised its position in Clearside Biomedical by 4.0% during the second quarter. ProShare Advisors LLC now owns 14,814 shares of the company’s stock worth $135,000 after acquiring an additional 563 shares in the last quarter. Bank of New York Mellon Corp raised its position in Clearside Biomedical by 10.8% during the first quarter. Bank of New York Mellon Corp now owns 34,823 shares of the company’s stock worth $277,000 after acquiring an additional 3,404 shares in the last quarter. Marshall Wace North America L.P. raised its position in Clearside Biomedical by 1.9% during the second quarter. Marshall Wace North America L.P. now owns 218,960 shares of the company’s stock worth $1,971,000 after acquiring an additional 4,010 shares in the last quarter. TIAA CREF Investment Management LLC raised its position in Clearside Biomedical by 30.7% during the first quarter. TIAA CREF Investment Management LLC now owns 19,257 shares of the company’s stock worth $153,000 after acquiring an additional 4,527 shares in the last quarter. Finally, Nationwide Fund Advisors raised its position in Clearside Biomedical by 118.3% during the second quarter. Nationwide Fund Advisors now owns 11,703 shares of the company’s stock worth $107,000 after acquiring an additional 6,343 shares in the last quarter. 52.45% of the stock is currently owned by hedge funds and other institutional investors.

A number of research firms recently issued reports on CLSD. TheStreet lowered shares of Clearside Biomedical from a “c-” rating to a “d” rating in a research note on Friday, August 11th. Zacks Investment Research lowered shares of Clearside Biomedical from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. ValuEngine lowered shares of Clearside Biomedical from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. Cowen and Company reiterated a “buy” rating on shares of Clearside Biomedical in a research note on Monday, August 7th. Finally, JMP Securities began coverage on shares of Clearside Biomedical in a research note on Thursday, May 25th. They issued an “outperform” rating and a $21.00 target price on the stock. Two investment analysts have rated the stock with a sell rating and six have issued a buy rating to the company. Clearside Biomedical has an average rating of “Buy” and a consensus target price of $19.00.

About Clearside Biomedical

Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.

Insider Buying and Selling by Quarter for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.